TOKYO —

Biomedical engineers at Duke University have achieved a significant breakthrough in stroke recovery research, developing an injectable biomaterial designed to transform the brain’s damaged tissue cavity into a more conducive environment for healing following an ischemic stroke. This innovative material has demonstrated in preclinical trials the ability to recruit the body’s own immune cells, stimulate the formation of new blood vessels, promote neural tissue regeneration, and ultimately improve motor function in animal models. The findings, published in the latest issue of Cell Biomaterials, offer a beacon of hope for the millions worldwide affected by this debilitating condition.

The Devastating Aftermath of Ischemic Stroke

Ischemic strokes, which occur when a blood clot obstructs blood flow to a portion of the brain, represent a leading cause of long-term disability and mortality globally. In the United States alone, an estimated 800,000 strokes occur annually, with ischemic strokes accounting for approximately 87% of all cases. While emergency interventions like clot-dissolving drugs and mechanical thrombectomy can be life-saving by restoring circulation and preserving viable brain tissue, they cannot reverse the damage to areas where brain cells have already perished.

The loss of brain tissue in severe strokes often results in the formation of a cavity. Post-stroke recovery, even after successful clot removal, largely relies on rehabilitation therapies. These therapies, while effective at helping surviving neural circuits adapt and compensate, do not directly address the structural void left by dead tissue. This limitation underscores a critical unmet need in stroke treatment: the development of strategies that actively promote tissue regeneration within the damaged brain.

"Once brain tissue has been lost, restoring blood flow is no longer enough," stated Tatiana Segura, the Robert Plonsey Distinguished Professor of Biomedical Engineering at Duke and senior author of the study. "Our goal is to engineer the injured space so that immune, vascular, and neural repair processes can begin to work together. We’re not just filling a void; we’re creating an active healing environment."

Engineering a Scaffold for Regenerative Repair

Segura and her research team set out to engineer a microenvironment within the stroke cavity that could simultaneously support multiple facets of the brain’s repair mechanisms. Their approach centers on a novel biomaterial known as microporous annealed particle scaffolds (MAPS). These scaffolds are composed of individual hydrogel microparticles that self-assemble into a porous, three-dimensional structure. The inherent porosity of these MAPS provides a physical framework that encourages cellular infiltration and migration, offering a stable substrate for rebuilding neural tissue.

Building upon earlier work that demonstrated the efficacy of MAPS in promoting tissue regeneration, the researchers aimed to leverage the body’s innate immune system to guide and amplify the repair process. A key focus of their strategy involved astrocytes, star-shaped glial cells that are critical for normal brain function and are among the first responders to brain injury.

Astrocytes communicate with neighboring cells, including other neural cells and immune cells, through the release of extracellular vesicles (EVs). These nanoscale packages encapsulate proteins, lipids, and genetic material, acting as intercellular messengers that can profoundly influence the behavior and function of recipient cells. The researchers hypothesized that by delivering specific signaling molecules embedded within these EVs, they could orchestrate a more robust and targeted repair response.

Concentrating Repair Signals for Maximum Impact

The team collected EVs from laboratory-grown astrocytes and then modified them with specific signaling molecules designed to attract beneficial immune cells, stimulate the formation of new blood vessels (angiogenesis), and promote overall functional recovery. A crucial aspect of their innovation lies in how these modified EVs were delivered. Instead of a simple injection, the scientists chemically attached the EVs to the surfaces of the hydrogel microparticles that form the MAPS scaffold.

This strategic immobilization of EVs had a profound effect: it ensured that the therapeutic signals remained concentrated within the engineered scaffold, dramatically increasing the likelihood that infiltrating cells would encounter and respond to them. "We are not simply placing a material into the brain," Segura explained. "We are engineering a local environment that can coordinate several parts of the repair response. This targeted delivery ensures that the therapeutic cues are available precisely where and when they are needed."

Through extensive experimentation, a particular combination of signaling molecules emerged as highly effective: interleukin-4 (IL-4) and C1q. This duo proved particularly adept at drawing a beneficial population of immune cells into the injured brain region. Among these recruited cells were macrophages, which are known to play a significant role in clearing debris and promoting tissue repair, and, unexpectedly, a persistent presence of neutrophils.

The Unexpected Role of Neutrophils in Stroke Recovery

Neutrophils are typically associated with acute inflammation and tissue damage during the initial phases of stroke. However, the new findings suggest a more nuanced and potentially beneficial role for these cells in the later stages of recovery, particularly when provided with the appropriate signaling cues and a supportive biomaterial environment.

The researchers conducted critical experiments to elucidate the importance of neutrophils. When they selectively reduced the neutrophil population within the influx of immune cells, they observed a substantial decline in the formation of new blood vessels and a diminished remodeling of the scaffold. This outcome strongly indicated that neutrophils were actively contributing to the healing process.

"This result fundamentally shifts how we perceive the role of neutrophils after stroke," commented Shangjing Xin, lead scientist on the study and a postdoctoral fellow in the Segura Laboratory. "Their function appears to be highly context-dependent, influenced by the timing of their arrival, their location within the injured site, and the specific signals they receive from their surroundings. Our study demonstrates a novel engineering strategy to recruit and retain these cells at the optimal time for therapeutic benefit."

Fostering Angiogenesis and Neural Regeneration

The influx of immune cells, guided by the engineered scaffold, was accompanied by a significant increase in the formation of new blood vessels throughout the stroke cavity. This process of angiogenesis is vital for restoring oxygen and nutrient supply to the damaged brain area, creating a more hospitable environment for neuronal survival and regeneration.

Furthermore, the researchers observed a notable increase in axonal fibers, both within and surrounding the injured region. Axons are the long projections of nerve cells that transmit electrical and chemical signals, and their regeneration is crucial for restoring neural connectivity and function. The presence of more axonal fibers suggests that the biomaterial scaffold is supporting the regrowth and reconnection of damaged neural pathways.

These biological improvements translated into tangible functional gains in the animal models. Mice treated with the optimized MAPS scaffold demonstrated significant improvements in motor coordination and dexterity. On a grid-walking test, designed to assess fine motor control and forelimb placement accuracy, the treated mice showed a remarkable reduction in errors. By eight weeks post-treatment, their performance on this test was statistically indistinguishable from that of healthy control mice, with the improvements persisting throughout the remainder of the study. This indicates a sustained and significant recovery of motor function.

The Indispensable Role of the Scaffold Architecture

To confirm the unique contribution of the biomaterial scaffold, the researchers conducted a critical control experiment. They administered the engineered extracellular vesicles without the MAPS scaffold to assess whether the EVs alone could elicit similar beneficial effects. The results were clear: the EVs delivered without the scaffold failed to produce comparable levels of blood vessel repair and functional recovery.

This finding underscores that the MAPS scaffold is not merely a passive delivery vehicle for therapeutic signals. Its porous architecture plays an active role by providing physical support and guiding cell infiltration. Moreover, its ability to concentrate the signaling molecules from the EVs within the damaged region appears to be paramount for orchestrating the complex cascade of repair processes. The combination of structural support and localized delivery of biochemical cues is therefore essential for the observed therapeutic benefits.

A Promising, Yet Early-Stage, Therapeutic Avenue

Despite the highly encouraging preclinical results, it is crucial to emphasize that this treatment approach remains in its early stages of development. The current research has been conducted using mouse models of stroke, where the biomaterial was injected directly into the damaged brain tissue.

Significant further research is required before this therapy can be considered for human clinical trials. Key areas of investigation will include comprehensive safety assessments, a more in-depth understanding of how different immune cell populations precisely contribute to the recovery process, and validation of the treatment’s efficacy in larger animal models that more closely mimic the complexity of human stroke.

An additional challenge lies in the source of the EVs. Currently, the researchers obtain these vesicles from primary rat astrocytes. As a next step, Segura’s laboratory is actively exploring the production of EVs from human induced pluripotent stem cell (iPSC)-derived astrocytes. This approach offers the potential for a more scalable and clinically relevant source of therapeutic EVs, while also providing greater control over the specific molecular cargo contained within them.

"You do not restore an ecosystem simply by containing the initial damage," Segura concluded. "You have to create the conditions that allow life to return. That is how we think about the stroke cavity. The material is not intended to reproduce the brain itself, but to create an environment where the body’s own cells can enter, communicate, and participate in rebuilding vascularized tissue. This is a paradigm shift in how we approach post-stroke rehabilitation." The development of this injectable biomaterial represents a significant stride toward realizing that ambitious vision.